Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PRNP | P04156 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2653673 | 0.95 | HDAC3 (0.50) | HDAC3HDAC4HDAC1HDAC6CYP4F2 | |
| SCHEMBL2654064 | 0.94 | POLB (0.49) | HDAC3HDAC4HDAC1HDAC6CYP4F2 | |
| SCHEMBL2655129 | 0.94 | POLB (0.49) | HDAC3HDAC4HDAC1HDAC6CYP4F2 | |
| SCHEMBL2653395 | 0.94 | POLB (0.49) | HDAC3HDAC4HDAC1HDAC6CYP4F2 | |
| SCHEMBL2653869 | 0.90 | HDAC3 (0.54) | HDAC3HDAC4HDAC1HDAC6CYP4F2 | |
| SCHEMBL5736276 | 0.86 | HDAC3 (0.53) | HDAC3HDAC4HDAC1HDAC6POLB | |
| SCHEMBL20772045 | 0.85 | HDAC3 (0.49) | HDAC3HDAC4HDAC1HDAC6POLB | |
| SCHEMBL2162296 | 0.84 | HPGD (0.52) | CYP4F2CYP4A11POLBTDP1HPGD | |
| SCHEMBL20772406 | 0.84 | POLB (0.48) | HDAC3HDAC4HDAC1HDAC6POLB | |
| SCHEMBL2653117 | 0.83 | HDAC3 (0.57) | HDAC3HDAC4HDAC1HDAC6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116583525-A | Pyrazoloazepine AKT inhibitor | 南京正大天晴制药有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-20230091810-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2023-03-23 | — | — | US | disclosed |
| EP-3725791-B1 | SALT SERVING AS AKT INHIBITOR AND CRYSTAL THEREOF | HARBIN ZHENBAO PHARMACEUTICAL CO LTD (CN) | 2023-03-15 | — | — | EP | disclosed |
| US-11384084-B2 | First-in-class of SHMT2 and MTHFD2 inhibitors as antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2022-07-12 | — | — | US | disclosed |
| WO-2022121788-A1 | PYRAZOLOAZEPINE AKT INHIBITOR | 南京正大天晴制药有限公司 | 2022-06-16 | — | — | WO | disclosed |
| CN-109311908-B | Dihydropyrazole azepinoids as Akt inhibitors | 哈尔滨珍宝制药有限公司 | 2021-05-07 | — | — | CN | disclosed |
| US-20210087205-A1 | SALT SERVING AS AKT INHIBITOR AND CRYSTAL THEREOF | Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) | 2021-03-25 | — | — | US | disclosed |
| US-20210047332-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | WAYNE STATE UNIVERSITY | 2021-02-18 | — | — | US | disclosed |
| EP-3725791-A1 | SALT SERVING AS AKT INHIBITOR AND CRYSTAL THEREOF | Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) | 2020-10-21 | — | — | EP | disclosed |
| US-10793573-B2 | First-in-class of SHMT2 and MTHFD2 inhibitors as antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190233434-A1 | DIHYDROPYRAZOLE AZEPINE COMPOUND SERVING AS AKT INHIBITOR | Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) | 2019-08-01 | — | — | US | disclosed |
| EP-3473628-A1 | DIHYDROPYRAZOLE AZEPINE COMPOUND SERVING AS AKT INHIBITOR | Medshine Discovery Inc. (CN) | 2019-04-24 | — | — | EP | disclosed |
| EP-3473628-A1 | DIHYDROPYRAZOLE AZEPINE COMPOUND SERVING AS AKT INHIBITOR | Medshine Discovery Inc. (CN) | 2019-04-24 | — | — | EP | disclosed |
| US-20190100524-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2019-04-04 | — | — | US | disclosed |
| WO-2019046612-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-03-07 | — | — | WO | disclosed |
| CN-109311908-A | Pyrazoline azatropylidene class compound as Akt inhibitor | 南京明德新药研发股份有限公司 | 2019-02-05 | — | — | CN | disclosed |
| EP-1957484-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | Eli Lilly & Company (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1856090-A2 | SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2007120284-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2006086488-A2 | SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047332-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | MTHFD1, SHMT1, SHMT2 | HDAC3 825/4885HDAC4 1605/4885HDAC1 1304/4885 |
| US-20190233434-A1 | DIHYDROPYRAZOLE AZEPINE COMPOUND SERVING AS AKT INHIBITOR | AKT3, AKT2, AKT1 | HDAC3 588/4885HDAC4 767/4885HDAC1 194/4885 |
| US-11384084-B2 | First-in-class of SHMT2 and MTHFD2 inhibitors as antitumor agents | MTHFD1, SHMT1, SHMT2 | HDAC3 825/4885HDAC4 1605/4885HDAC1 1304/4885 |
| US-20210087205-A1 | SALT SERVING AS AKT INHIBITOR AND CRYSTAL THEREOF | AKT1, AKT2, AKT3 | HDAC3 1153/4885HDAC4 973/4885HDAC1 166/4885 |
| US-20230091810-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | MTHFD1, SHMT1, SHMT2 | HDAC3 962/4885HDAC4 1765/4885HDAC1 1494/4885 |
| US-20190100524-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | SHMT2, MTHFD1, SHMT1 | HDAC3 913/4885HDAC4 1930/4885HDAC1 1104/4885 |
| US-10793573-B2 | First-in-class of SHMT2 and MTHFD2 inhibitors as antitumor agents | SHMT2, MTHFD1, SHMT1 | HDAC3 913/4885HDAC4 1930/4885HDAC1 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.